STOCK TITAN

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

Rhea-AI Summary

Gilead Sciences announced results from the ZUMA-7 trial, the first Phase 3 study of CAR T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). Yescarta showed superior two-year event-free survival (EFS) rates of 40.5% compared to 16.3% for the standard of care (SOC). The study enrolled 359 patients and demonstrated improved quality of life for those treated with Yescarta. Regulatory filings to expand Yescarta's indication are in progress, with the FDA granting Priority Review status, targeting a decision by April 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Gilead Sciences (GILD) presented new data from the Phase 3 ASCENT study on Trodelvy (sacituzumab govitecan) in Black patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC). The study showed a 56% reduction in the risk of disease worsening or death, with a median progression-free survival (PFS) of 5.4 months versus 2.2 months for chemotherapy. Overall survival also improved to 13.8 months compared to 8.5 months for chemotherapy. Trodelvy demonstrated a higher overall response rate of 32% compared to 6% for chemotherapy. Safety profiles were consistent with earlier findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
Rhea-AI Summary

Gilead Sciences has selected AWS as its preferred cloud provider to enhance its clinical trial design and data-driven decision-making capabilities. This collaboration will leverage AWS's machine learning and analytics to refine Gilead's drug pipeline while ensuring patient privacy and data security. Gilead will also implement SAP S/4HANA for its enterprise resource planning, aiming for increased operational efficiency. Additionally, over 50% of its data center footprint will be migrated to AWS, which supports IT transformation and improved disaster recovery processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
Rhea-AI Summary

Gilead Sciences (NASDAQ: GILD) will present new data from the Phase 3 ASCENT study of Trodelvy at the San Antonio Breast Cancer Symposium (December 7-10). The analyses focus on treatment outcomes for Black patients with metastatic triple-negative breast cancer (TNBC) and post-progression therapy outcomes. Trodelvy is indicated for patients with metastatic TNBC who have received prior systemic therapies. The study highlights Trodelvy's potential in addressing high unmet needs in cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

The European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan), developed by Gilead Sciences (GILD), for treating adult patients with metastatic triple-negative breast cancer (TNBC) after two or more therapies. The approval is supported by Phase 3 ASCENT study results, showing a 49% reduction in death risk and improved overall survival (11.8 months vs. 6.9 months). This is a significant treatment option for this aggressive cancer type, which has a five-year survival rate of only 12%. Trodelvy is also approved in several other countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
Rhea-AI Summary

Gilead Sciences (GILD) has submitted a Biologics License Application (BLA) for bulevirtide, an investigational treatment for chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease. If approved, it will be the first treatment option in the U.S. for this condition. The submission is backed by Phase 2 and 3 study data, showing 36.7% response after 24 weeks with bulevirtide 2 mg. The drug has received Breakthrough Therapy and Orphan Drug designations from the FDA, emphasizing its potential significance in addressing severe liver disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
Rhea-AI Summary

Gilead Sciences (Nasdaq: GILD) announced its participation in the Evercore ISI Annual HealthCONx Conference on Thursday, December 2 at 2:40 PM ET. Investors can access a live webcast on the company’s investors page, with a replay available for 30 days post-presentation. Gilead is a biopharmaceutical leader committed to innovative treatments for serious diseases including HIV, viral hepatitis, and cancer, operating in over 35 countries from its headquarters in Foster City, California.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
-
Rhea-AI Summary

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including anti-TIGIT agents domvanalimab and AB308, as well as etrumadenant and quemliclustat. This move involves $725 million in option payments to Arcus. The companies are set to co-develop these candidates, share global costs, and explore innovative treatment combinations. Antitrust clearance is required, with expected closure by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary

Gilead Sciences has exercised options for three clinical-stage programs from Arcus Biosciences, including domvanalimab, AB308, etrumadenant, and quemliclustat. The agreement, subject to antitrust clearance, results in Arcus receiving $725 million in option payments. The collaboration aims to accelerate the clinical development of these programs, which target hard-to-treat cancers like lung and pancreatic cancer. Notably, Gilead will pursue novel treatment combinations, enhancing its oncology portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Rhea-AI Summary

Gilead Sciences announced that the EVER-132-001 trial of sacituzumab govitecan (Trodelvy) met its primary endpoint with an objective response rate (ORR) of 38.8% in patients with metastatic triple-negative breast cancer (TNBC) who received prior therapies. The trial, conducted in China, included 80 patients and demonstrated consistent results with previous studies. No new safety signals were identified. The company is preparing for a product launch in China, emphasizing the potential impact on treatment for patients with limited options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $93.95 as of December 24, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 117.1B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

GILD Stock Data

117.09B
1.24B
0.12%
88.4%
1.45%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY